SRC-3-IN-1 (compound SI-10) is an inhibitor of steroid receptor coactivator 3 (SRC-3) with an IC50 of 3.3 μM. It features good water solubility, oral bioavailability, and selectivity. SRC-3-IN-1 is applicable for prostate cancer research.

SRC-3-IN-1 demonstrates high potency against various cancer cell lines at different concentrations over 72 hours. Additionally, SRC-3-IN-1 exhibits significant selectivity for its intended target compared to non-targets, with effectiveness in the single-digit nanomolar range.

SRC-3-IN-1 administered orally at doses of 50 and 100 mg/kg for 4 consecutive weeks does not lead to weight loss in mice. When given intraperitoneally at 10 mg/kg daily for 4 weeks, it extends mouse survival by inhibiting tumor angiogenesis. Additionally, a daily intraperitoneal dose of 10 mg/kg over 4 weeks reduces the tumor-to-femur area ratio by more than 50%.